Ciaran Lawlor [Campfire Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Ciaran Lawlor ======

{{ ::ciaran_lawlor.png?200|}}

**Ciaran Lawlor** is an American biotechnology entrepreneur based in [[united_states:massachusetts:Boston]], [[united_states:Massachusetts]].

===== History =====

==== Education ====

Lawlor graduated from [[Maynooth University]], completing a 3 month lab placement at [[Kings College London]]. He then received credentials from the [[Royal College of Surgeons in Ireland]] (RCSI).((//Ciaran Lawlor.// LinkedIn. Retrieved June 14, 2023, from https://www.linkedin.com/in/ciaran-lawlor-919546b/)) 

==== Career ====

From October 2011 to November 2013, Lawlor worked at [[pharmaceutical_companies:PULMATRiX]], focusing on "formulation development for pre-clinical studies with small molecules, antibiotics, macromolecules and new chemical entities."((//Ciaran Lawlor.// LinkedIn. Retrieved June 14, 2023, from https://www.linkedin.com/in/ciaran-lawlor-919546b/))

He then went to work at [[pharmaceutical_companies:Moderna]], where he "helped build internal capabilities on nanoparticle formulation including growing formulation team and acting as lead delivery technology scientist on key strategic partnerships."

In January 2016, Lawlor was hired at the [[Boston Consulting Group]] (BCG), where he was quickly promoted to Principal.

=== COVID-19 ===

Lawlor co-authored a paper titled "The Near-Term Outlook for COVID-19 Therapeutic Treatments" published by the [[Boston Consulting Group]] on May 8, 2020. The paper presented a favourable outlook for the use of the experimental drug [[remdesivir]] over a variety of other options to treat [[COVID-19]]. Lawlor's co-authors were [[Jordon Walker]], [[Ahad Wahid]] and [[Josh Kellar]].((Lawlor, C., Wahid, A., Walker, J., & Kellar, J. (2020). //The Near-Term Outlook for COVID-19 Therapeutic Treatments.// Boston Consulting Group. https://web.archive.org/web/20230422204237/https://web-assets.bcg.com/img-src/BCG-The-Near-Term-Outlook-for-COVID-19-Therapeutic-Treatments-May-2020_tcm9-246799.pdf))

A follow-up article was published on May 14, 2020, titled "The Timelines and Implications for COVID-19 Vaccines". It was co-authored with Kellar, Wahid, [[Emily Serazin]], [[Andrew Rodriguez]] and [[Philip Berk]].((Lawlor, C., Kellar, J., Serazin, E., Rodriguez, A., Berk, P., & Wahid, A. (2020, May 14). //The Timelines and Implications for COVID-19 Vaccines.// Boston Consulting Group. http://archive.today/2023.06.14-235609/https://www.bcg.com/en-ca/publications/2020/covid-vaccines-timelines-implications))

In April 2021, Lawlor left BCG to become Chief Operating Officer of [[pharmaceutical_companies:ReNAgade Therapeutics]].((//Team.// ReNAgade Therapeutics. Retrieved June 14, 2023, from https://web.archive.org/web/20230614231455/https://renagadetx.com/team/))

===== Patents =====

  * [[http://archive.today/2023.06.15-003024/https://patents.google.com/patent/US11235112B2/en?q=(Inhalable+dry+powders)&oq=Inhalable+dry+powders|Inhalable dry powders]]
  * [[https://patents.google.com/patent/WO2016118724A1/en?oq=2016118724|Lipid nanoparticle compositions]]

===== External links =====

  * [[http://covidtruthinitiative.ca/e/en/Individuals/Ciaran-Lawlor|COVID Truth Initiative]]
  * [[https://www.linkedin.com/in/ciaran-lawlor-919546b/|LinkedIn]]